Anti-PD-1 immunotherapyImmune checkpoint inhibitorsNivolumabPembrolizumabImmunotherapy with immune checkpoint inhibitors, such as anti-PD-1 drugs, is an area in increasing development for its efficacy and advantages in the treatment of advanced metastatic melanoma. In fact, immunotherapy has been the ...
Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346.2.Lu S, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from ...
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions. Once a drug...
Anti-PD-1 monoclonal antibody, produced by Suzhou Pharmaceutical Enterprise and first developed by China, was put into operation on Dec. 17, 2018 after it was approved for sale under the trade name "Tuo Yi". The price of the drug was officially announced on January 8, 7200 yuan (240 mg)...
Furthermore, our in vivo studies revealed that inhibiting S100A9 can synergistically enhance the efficacy of anti-PD-1 drugs in the eradication of hepatocellular carcinoma. Conclusions Our study underscores the significance of S100A9+CD14+ monocytes in predicting inadequate response to ICB treatment and...
Borrowing this knowledge should lead to revised regimens of combination therapy incorporating immune checkpoint inhibitors and antibiotics, as well as repurposed drugs for the effective management of chronic diseases. Funding This work has been supported by grants to MM (Swedish Heart and Lung ...
PURPOSE: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response co... JM Taube,A Klein,JR Brahmer,... - 《Clinical Cancer Research》 被引量: 2019发表: 2014年 ...
drugs are excreted in human milk, instruct women to discontinue nursing during treatment with KEYTRUDA and for 4 months after the final dose. There is limited experience in pediatric patients. In a study, 40 pediatric patients (16 children aged 2 years to younger than 12 year...
PD-L2 expression as a predictive biomarker for the response to anti-PD-1 drugs in non-small cell lung cancer patientsPD-L2 expression as a predictive biomarker for the response to anti-PD-1 drugs in non-small cell lung cancer patientsdoi:10.1093/annonc/mdy375.069Shinkichi...
Recently, some targeted drugs have been found to remarkably enhance the anti-tumor immunity of cancer models, mainly through increasing the level of CD8+ T cells, M1-type macrophages, expression of PD-L1, and decreasing the level of regulatory T cells and M2 macrophages. The above finding ...